Present and future aspects of dydrogesterone in prevention or treatment of pregnancy disorders: an outlook

References

1. Schindler AE. First trimester endocrinology. Consequences for diagnosis and treatment of pregnancy failures. Gynecol Endocrinol 2004;18:51–7.10.1080/09513590310001651795Suche in Google Scholar

2. Csapo AI, Pulkinen MO, Ruttner B, Sauvage JP, Wiest WG. The significance of the human corpus luteum in pregnancy maintenance. Am J Obstet Gynecol 1972;112:1061–7.10.1016/0002-9378(72)90181-0Suche in Google Scholar

3. McCord ML, Arheart KL, Muram D, Stovall TG, Buster JE, Carson SE. Single serum progesterone as a screen for ectopic pregnancy, enhancing specificity and sensitivity to obtain optimal test performance. Fert Steril 1996;66:513–6.10.1016/S0015-0282(16)58560-4Suche in Google Scholar

4. Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol 2012;28:983–90.10.3109/09513590.2012.702875Suche in Google Scholar PubMed PubMed Central

5. Schindler AE, Carp H, Druckmann R, Genazzani AR, Huber J, Pasqualini J, Schweppe KW, Szekeres-Bartho J. Guidelines of the European Progestogen Club for treatment or prevention of threatened or recurrent (habitual) miscarriage. Gynecol Endocrinol 2015;15:447–9.10.3109/09513590.2015.1017459Suche in Google Scholar PubMed

6. Wahabi HA, Fayed AA, Esmail SA, Elawad M. Progestogen for treating threatened miscarriage. Cochrane Data Base Syst Rev 2011;12:CD005943.10.1002/14651858.CD005943.pub3Suche in Google Scholar PubMed

7. Saraswat L, Bhattacharya S, Maheshwan A, Bhattacharya S. Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: a systematic review. Br J Obstet Gynaecol 2010;117:245–57.10.1111/j.1471-0528.2009.02427.xSuche in Google Scholar PubMed

8. Jauniaux E, Vav Oppenraaji RH, Burton GJ. Obstetric outcome after early placental complications. Curr Opin Obstet Gynecol 2010;22:452–7.10.1097/GCO.0b013e3283404e44Suche in Google Scholar PubMed

9. Ahmed SR, El-Sammani M, Al-Sheeha MA, Aitallah AS, Jabin Khan F, Ahmed SR. Pregnancy outcome in women with threatened miscarriage: a year study. Mat Soc Med 2012;24:26–8.10.5455/msm.2012.24.26-28Suche in Google Scholar PubMed PubMed Central

10. Salazar El, Calzada L. The role of progesterone in endometrial estradiol- and progesterone receptor synthesis in women with menstrual disorders and habitual abortion. Gynecol Endocrinol 2007;23:222–5.10.1080/09513590701254030Suche in Google Scholar PubMed

11. Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, Gupta P, Dawood F, Koot YE, Bender Atik R, Bloemenkamp KW, Brady R, Briley AL, Cavallaro R, Cheong YC, Chu JJ, Eapen A, Ewies A, Hoek A, Kaaijk EM, Koks CA, Li TC, MacLean M, Mol BW, Moore J, Ross JA, Sharpe L, Stewart J, Vaithilingam N, Farquharson RG, Kilby MD, Khalaf Y, Goddijn M, Regan L, Rai R. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med 2015;373:2141–8.10.1056/NEJMoa1504927Suche in Google Scholar PubMed

12. Kumar A, Beguin N, Prasat S, Aggarwal S, Sharma SH. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, placebo-controlled trial. Fert Steril 2014;102:1354–7.10.1016/j.fertnstert.2014.07.1251Suche in Google Scholar PubMed

13. Ghosh S, Chattopadhyay R, Goswani S, Chaudhury K, Chakravarty B, Ganesh A. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. J Obstet Gynaecol Res 2014;40:1871–6.10.1111/jog.12456Suche in Google Scholar PubMed

14. Carp H. A systematic review of dydrogesterone for the treatment of recurrent miscarriage. Gynecol Endocrinol 2015;31:422–30.10.3109/09513590.2015.1006618Suche in Google Scholar PubMed

15. Armstrong J. 17-Progesterone for preterm birth prevention: a potential US§ 2 billion opportunity. Am J Obstet Gynecol 2007;196:194–5.10.1016/j.ajog.2006.12.022Suche in Google Scholar PubMed

16. Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–24.10.1067/mob.2003.41Suche in Google Scholar PubMed

17. Schindler AE. Progestogens for treatment and prevention of pregnancy disorders. Horm Mol Biol Clin Invest 2010;3:453–60.10.1515/hmbci.2010.069Suche in Google Scholar PubMed

18. Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynecol 1990;9:149–54.10.1111/j.1471-0528.1990.tb01740.xSuche in Google Scholar PubMed

19. Romero R, Nicoleides K, Conde-Agudelo A, Tabor A, OʼBrien JM, Cetingoz E, Da Fonseca E, Creasy GW, Klein K, Rode L, Soma-Pillay P, Fusey S, Cam C, Alfirevic Z, Hassan SS. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual based data. Am J Obstet Gynecol 2012;206:124e1–19.10.1016/j.ajog.2011.12.003Suche in Google Scholar PubMed PubMed Central

20. Gonzalez-Quintero VH, Cordova YC, Istwan NB, Tudela F, Rhea DJ, Romary LM, Marimon A, Desch CN, Stanziano GJ. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery. Am J Obstet Gynecol 2011;205:275–9.10.1016/j.ajog.2011.06.043Suche in Google Scholar PubMed

21. Khashani AS, McNamee R, Abel KM. Rates of preterm birth for antenatal exposure to score life events: a population-based cohort study. Hum Reprod 2009;24:429–37.10.1093/humrep/den418Suche in Google Scholar PubMed

22. Blois SM, Joachim R, Kandil J, Margni R, Tometten M, Klapp BF, Arck PC. Depletion of CD8⁺ cells abolishes the pregnancy protective effect of progesterone substitution with dydrogesterone in mice by altering the Th1/Th2 cytokine profile. J Immunol 2004;172:5893–9.10.4049/jimmunol.172.10.5893Suche in Google Scholar PubMed

23. Hudic H, Skekeres-Bartho J, Fatusic Z, Stray-Pedersen B, Dizdarević-Hudić L, Latifagić A, Hotić N, Kamerić L, Mandžić A. Dydrogesterone supplementation in women with threatened preterm delivery – the impact on cytokine profile, hormone profile and progesterone induced blocking factor. J Reprod Immunol 2011;92:103–7.10.1016/j.jri.2011.08.006Suche in Google Scholar PubMed

24. Ragab MI, Sammour MB, ElKabarity H, Hegazy MR. Progesterone: a treatment for preeclamptic toxaemia. Ain Shams Med J 1971;22:9–24.Suche in Google Scholar

25. Sammour MB, El Makhzangy MN, Fawzy MM, Schindler A. Progesterone therapy in pregnancy induced hypertension: therapeutic value and hormonal profile. Clin Exp Hypertens B 1982;1:475–8.10.3109/10641958209009619Suche in Google Scholar PubMed

26. Zainul RM, Lim JF, Nawaun NH, Luqman M, Zolkeplai MF, Rangkuty HS, Mohamd Nor NA, Tamil A, Shah SA, Tham SW, Schindler AE. A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in pregnancy. Gynecol Endocrinol 2014;30:217–20.10.3109/09513590.2013.860960Suche in Google Scholar PubMed